[Form 4] BIO-TECHNE Corp Insider Trading Activity

Bio-Techne director Amy E. Herr reported routine equity activity on 02/03/2026, mainly involving awards held by her significant other.

Rhea-AI Filing Summary

Bio-Techne director Amy E. Herr reported routine equity activity on 02/03/2026, mainly involving awards held by her significant other. On that date, 38 restricted stock units converted into 38 shares of common stock at $0, all held indirectly through her significant other.

To cover withholding obligations, 16 indirectly held common shares were disposed of at $64.63 per share, leaving 2,176 common shares indirectly held by her significant other and 2,680 shares held directly. The filing also lists multiple stock options and additional restricted stock units with vesting dates from 2026 through 2035, all either directly held or indirectly held through her significant other.

Insider Trade Summary

38 shares exercised/converted

Exercise 17 txns

Insider Herr Amy E.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	38	$0.00	$0.00
Exercise	Common Stock	38	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	16	$64.63	$1K
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 1,447 contracts for 1,370 underlying shares (Indirect, By significant other); Common Stock — 2,176 shares (Indirect, By significant other); Stock Option (Right to Buy) — 6,192 contracts (Direct); Stock Option (Right to Buy) — 20,919 contracts (Indirect, By significant other); Common Stock — 2,680 shares (Direct)

Footnotes (12)

1. F1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
2. F2. Fully vested.
3. F3. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
4. F4. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
5. F5. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
6. F6. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
7. F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
8. F8. 118 restricted stock units vest on 8/15/2026.
9. F9. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
10. F10. 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
11. F11. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
12. F12. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herr Amy E.

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								2,680	D
Common Stock	02/03/2026		M		38	A	$0	2,192	I	By significant other
Common Stock	02/03/2026		F		16	D	$64.63	2,176	I	By significant other

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.05							10/24/2025	02/03/2035	Common Stock	2,415		2,415	D
Stock Option (Right to Buy)	$60.96							(1)	10/30/2035	Common Stock	3,777		3,777	D
Stock Option (Right to Buy)	$47.6							(2)	08/07/2026	Common Stock	6,636		6,636	I	By significant other
Stock Option (Right to Buy)	$66.97							(2)	08/05/2027	Common Stock	4,472		4,472	I	By significant other
Stock Option (Right to Buy)	$120.46							(2)	08/06/2028	Common Stock	2,076		2,076	I	By significant other
Stock Option (Right to Buy)	$94.52							(3)	08/15/2029	Common Stock	2,104		2,104	I	By significant other
Stock Option (Right to Buy)	$84.61							(4)	08/15/2030	Common Stock	1,084		1,084	I	By significant other
Stock Option (Right to Buy)	$74.91							(5)	08/15/2034	Common Stock	1,468		1,468	I	By significant other
Stock Option (Right to Buy)	$72.05							(6)	02/03/2035	Common Stock	344		344	I	By significant other
Restricted Stock Units	(7)							(8)	(8)	Common Stock	118		118	I	By significant other
Restricted Stock Units	(7)							(9)	(9)	Common Stock	320		320	I	By significant other
Restricted Stock Units	(7)	02/03/2026		M			38	(10)	(10)	Common Stock	38	$0	77	I	By significant other
Restricted Stock Units	(7)							(11)	(11)	Common Stock	932		932	I	By significant other
Stock Option (Right to Buy)	$53.6							(12)	08/15/2035	Common Stock	2,735		2,735	I	By significant other

Explanation of Responses:

1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

2. Fully vested.

3. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.

4. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.

5. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

6. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.

7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

8. 118 restricted stock units vest on 8/15/2026.

9. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.

10. 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.

11. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.

12. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.